Organogenesis Holdings Inc(ORGO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:10 PM ET (Korea 9/12 05:10)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.83 | Insider Own | 44.67% | Shs Outstand | 128.7M | Perf Week | -9.15% |
| Market Cap | 0.19B | Forward P/E | - | EPS next Y | 77.51% | Insider Trans | 0.03% | Shs Float | 71.2M | Perf Month | -17.68% |
| Enterprise Value | 0.35B | PEG | - | EPS next Q | -0.18 | Inst Own | 51.63% | Short Float | 20.01% | Perf Quarter | -37.39% |
| Income | -0.11B | P/S | 0.42 | EPS this Y | -575.73% | Inst Trans | 5.25% | Short Ratio | 17.52 | Perf Half Y | -43.77% |
| Sales | 0.46B | P/B | 1.29 | EPS next 5Y | - | ROA | -19.4% | Short Interest | 14.25M | Perf YTD | -71.24% |
| Book/sh | 1.15 | P/C | 4.09 | EPS past 3/5Y | 9.43% -0.14% | ROE | -25.92% | 52W High | -78.95% ($7.08) | Perf Year | -70.44% |
| Cash/sh | 0.36 | P/FCF | 9.2 | Sales past 3/5Y | 7.76% 10.77% | ROIC | -24.34% | 52W Low | 0% ($1.49) | Perf 3Y | -42.91% |
| Dividend Est. | - | EV/EBITDA | 42.68 | EPS Y/Y TTM | -613.22% | Gross Margin | 63.15% | Volatility(W/M) | 5.6% 5.51% | Perf 5Y | -91.09% |
| Dividend TTM | - | EV/Sales | 0.77 | Sales Y/Y TTM | 6.5% | Oper. Margin | -5.4% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3 | EPS Q/Q | -702.49% | Profit Margin | -23.14% | RSI (14) | 29.48 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.52 | Sales Q/Q | -56.68% | SMA20 | -12.48% ($1.7) | Beta | 1.26 | Target Price | $2 |
| Payout | - | Debt/Eq | 0.23 | Earnings | 2026/8/6 | SMA50 | -28.91% ($2.1) | Rel Volume | 1.04 | Prev Close | $1.53 |
| Employees | 854 | LT Debt/Eq | 0.2 | EPS/Sales Surpr. | -103.91% -19.38% | SMA200 | -50.7% ($3.02) | Avg Volume(3M) | 0.81M | Price | $1.49 |
| IPO | 2017/1/5 | Option/Short | Yes/Yes | Trades | 4854 | Volume | 844,141 | Change | -2.61% |
Company
ORGO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩹 This U.S. healthcare company develops, manufactures, and sells regenerative medicine products targeting the advanced wound care, surgical, and sports medicine markets. It operates a single business segment with a portfolio of skin substitute and soft-tissue regeneration solutions—including Apligraf and PuraPly—and has established a strong presence in the chronic wound care field, particularly in the treatment of diabetic foot ulcers.
Over the past 1 year, on the lower side
79% below its 1-year high.
ORGO has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -575.7% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -42.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 51.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
IVSS 0.00%
VFQY 0.00%
FLQS 0.00%
QSML 0.00%It ranks #4 in the industry
Based on market cap of $192M.
ORGO $192M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is ORGO?
ORGO belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ORGO?
The market cap of ORGO is approximately $192M, ranking 4,159 within its sector.
What is the 52-week high and low for ORGO?
ORGO has recorded a 52-week high of $7.08 and a low of $1.49.
